Chardan Capital Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $38.00

Dyne Therapeutics (NASDAQ:DYN) had its price target dropped by stock analysts at Chardan Capital from $50.00 to $38.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s target price indicates a potential upside of 283.45% from the company’s current price.

A number of other research firms have also weighed in on DYN. Sanford C. Bernstein began coverage on shares of Dyne Therapeutics in a report on Tuesday, June 24th. They issued a “market perform” rating and a $13.00 target price for the company. Oppenheimer began coverage on shares of Dyne Therapeutics in a research note on Monday, June 2nd. They set an “outperform” rating and a $34.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Jones Trading began coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Robert W. Baird dropped their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating for the company in a research note on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.13.

Dyne Therapeutics Trading Up 7.7%

DYN stock opened at $9.91 on Tuesday. The firm has a fifty day moving average price of $10.79 and a 200 day moving average price of $11.55. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The company has a debt-to-equity ratio of 0.17, a quick ratio of 20.35 and a current ratio of 16.83. The firm has a market cap of $1.41 billion, a PE ratio of -2.57 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.02. Sell-side analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox bought 100,000 shares of the firm’s stock in a transaction dated Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the transaction, the chief executive officer owned 242,179 shares in the company, valued at $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 14.14% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DYN. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics in the fourth quarter worth approximately $50,000. GAMMA Investing LLC increased its holdings in shares of Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company’s stock valued at $251,000 after acquiring an additional 2,345 shares during the period. CWM LLC increased its holdings in shares of Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after acquiring an additional 1,900 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock worth $32,000 after acquiring an additional 2,446 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Dyne Therapeutics during the 1st quarter worth $47,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.